To study the influence of Jinkuishenqiwan adjuvant therapy on immune function in adult bronchial asthma in remission stage patients.Methods:One hundred and ten cases of adult bronchial asthma in remission stage patients in our hospital during July 2013 to April 2016 were chosen as research subject,treatment methods were reviewed and all patients were divided into control group(n＝58)underwent normal western medicine treatment only,observation group(n＝52)underwent Jinkuishenqiwan adjuvant therapy plus normal western medicine treatment.Before and after treatment,peripheral blood Th17/Treg cell ratio,serum Th1/Th2 cytokines and humoral immune indexes between two groups were compared.Results:Before treatment,there were no significant difference between two groups about peripheral blood Th17/Treg cell ratio,serum Th1/Th2 cytokines and humoral immune indexes(P>0.05).After treatment,Th17 cells and the ratio of Th17/Treg in observation group in peripheral blood were lower than those in control group,Treg cells was higher than that in control group; serum contents of IL-2,IFN-γ were higher than those in control group,IL-4,IL-5 were lower than those in control group;serum contents of humoral immunity indexes such as IgE、C3 were lower than that in control group(P<0.05).Conclusion:Jinkuishenqiwan adjuvant therapy can relieve the cellular immunity,humoral immune function in patients with optimization of adult bronchial asthma,has positive clinical significance.